Global pharmaceutical major, Zydus Cadila announced on Wednesday that its plasmid DNA vaccine to prevent COVID-19, namely ZyCoV-D, was found to be well-tolerated and safe in phase 1 clinical trial.

Pharma major, Lupin Limited had announced on Tuesday that it has received regulatory approval from United States Food and Drug Administration (USFDA) for its Empagliflozin tablets, 10 mg and 25 mg to market a generic version of Jardiance tablets, 10 mg, and 25 mg, of Boehringer Ingelheim Pharmaceuticals.

Most people believe in the phrase, ‘the more the merrier’. However, that might not hold true with mutual funds. Read on to find out why.

The consolidated net sales reported in Q1FY21 came in at Rs 3,639.9 crore, which increased by 4.11 per cent YoY from Rs 3,496.3 crore in Q1FY20. 

The market opened in green on August 5, 2020. 

The market opened in green on August 5, 2020, overall volumes in futures & options currently stand at 2,11,51,827 crore contracts with a turnover of Rs. 14,46,632.04 crore.

The market opened in green on August 5, 2020, overall volumes in futures & options currently stand at 2,11,51,827 crore contracts with a turnover of Rs. 14,46,632.04 crore.

Alembic Pharmaceuticals Limited has received final approval from United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Vardenafil Hydrochloride tablets, 2.5 mg (base), 5 mg (base), 10 mg (base), and 20 mg (base).

The promoters have released 27 lakh equity shares, with reference to the earlier announcements. The promoters have informed the company that they have repaid Rs 58.09 crore and now the outstanding amount is Rs 5.91 crore.

The company also reported its first-quarter result of FY21 on Tuesday where it recorded revenue of Rs 32.24 crore as against Rs 35.87 crore in Q1FY20. It posted PAT of Rs 8.63 crore in the quarter as against Rs 10.04 crore in Q1FY20